Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Prashant Jani"'
Autor:
Christopher Brian Abraham, Prashant Jani, Roxanne Turuba, Michael Campbell, Ingeborg Zehbe, Laura Curiel
Publikováno v:
Journal of Nanotechnology, Vol 2017 (2017)
We characterized in vivo a functional superparamagnetic iron-oxide magnetic resonance contrast agent that shortens the T2 relaxation time in magnetic resonance imaging (MRI) of prostate cancer xenografts. The agent was developed by conjugating Molday
Externí odkaz:
https://doaj.org/article/1ba043ea0c8a43ebb7457a264b2cfb02
Autor:
Prashant Jani, Vijay H .Satav
Publikováno v:
Journal of Krishna Institute of Medical Sciences University, Vol 01, Iss 02, Pp 163-167 (2012)
Technology for acquisition of virtual slides was developed in 1985; however, it was not until the late 1990s that desktop computers had enough processing speed to commercialize virtual microscopy and apply the technology to education. By 2000, the pr
Externí odkaz:
https://doaj.org/article/c76265050116473aaa1e8ba7682d2f24
Autor:
Pritam Tayshetye, Andrew J. Friday, Ashten N. Omstead, Stacey Miller, Ping Zheng, Prashant Jani, Tanvi Verma, Ali Zaidi, Gene Finley
Publikováno v:
Cancers; Volume 15; Issue 1; Pages: 276
Background: In rectal cancer treatment, neoadjuvant chemoradiation therapy (CRT) is the standard of care and reduces local failure rate. The tumor microenvironment (TME) is a complex entity comprising of tumor cells, immune cells and surrounding stro
Autor:
Laura Curiel, Christopher Brian Abraham, Ingeborg Zehbe, Prashant Jani, Roxanne Turuba, Michael Campbell
Publikováno v:
Journal of Nanotechnology, Vol 2017 (2017)
We characterized in vivo a functional superparamagnetic iron-oxide magnetic resonance contrast agent that shortens the T2 relaxation time in magnetic resonance imaging (MRI) of prostate cancer xenografts. The agent was developed by conjugating Molday
We report a case of an extremely rare histologic combination of pilomatrix or pilomatrical carcinoma with admixed melanocytes within the same tumor mass. Pilomatrix carcinoma is a neoplasm of low-grade malignancy that is characterized by a tendency f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a0d122abd96ab19fa7902ac1cebea98
https://ora.ox.ac.uk/objects/uuid:412f0bc5-5bbb-4465-9477-d76ab85ffdba
https://ora.ox.ac.uk/objects/uuid:412f0bc5-5bbb-4465-9477-d76ab85ffdba
Publikováno v:
Pediatric and Developmental Pathology. 15:259-264
The D2-40 antigen is a glycosylated sialomucin that is strongly expressed by lymphatic endothelial cells. Recently we observed the expression of D2-40 on the luminal surface of pulmonary airspaces in lung sections. The aim of the study was to assess
Publikováno v:
Current Opinion in Clinical Nutrition and Metabolic Care. 11:27-31
This review provides current strategies for weight management in the elderly population as it can be different from young adults due to multiple factors: co-morbidities, polypharmacy, limitation of functional activities, social issues.The recommendat
Autor:
Chen Wang, Donna E. Reece, Alden Chesney, Hong Chang, Ken H. Young, Prashant Jani, Connie Qi, Allan Jiang, Young Trieu, Christine Chen
Publikováno v:
Clinical Lymphoma and Myeloma. 9:36-38
The deletion of the long arm of chromosome 6 is the most common cytogenetic abnormality in Waldenstrom's macroglobulinemia (WM), but its prognostic significance is unclear. We investigated 77 patients with WM by interphase cytoplasmic immunoglobulin
Publikováno v:
The Canadian journal of urology. 15(2)
A case of synchronous adrenocortical carcinoma (ACC) and renal cell carcinoma (RCC) has not yet been described in the English medical literature, to our knowledge. We report a first such case of adrenocortical and renal cell carcinomas occurring simu
Publikováno v:
American journal of hematology. 82(1)
By multiparameter flow cytometry, the T-cell-associated markers CD4 and CD7 were aberrantly coexpressed on a case of B-cell chronic lymphocytic leukemia (CLL). The CLL had an immunophenotype: CD19+, CD20+, CD79b+, CD5+, CD23+, FMC7+, kappa+, CD4+, an